Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X (OTCQB:KARX) to Present Global Growth Strategy and Showcase SkyXero at 26th MK-Equity Investment Conference in Munich25.9.2026 14:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / September 25, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it will present at the 26th MK-Equity Investment Conference on September 30, 2026, in Munich, Germany. Chad Clovis, Chief Executive Officer, will present Karbon-X's equity story and global growth strategy to the conference audience. Investors and shareholders interested in connecting with Chad while he is in Munich are welcome to reach out to arrange a time to meet by contacting investors@karbon-x.com. The invitation-only conference is hosted by MK-Equity, the family office of Michael Kott. MK-Equity and Mr. Kott are significant investors in Karbon-X. The conference brings together family offices, high-net-worth individuals, active investors and entrepreneurs across a range of industries and is built around an ecosystem of like-minded investors focused on the intersection of people and megatrends. During
Fermi Selects CBRE to Operate and Maintain Its First Data Center24.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 24, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that its subsidiary, Fermi Services LLC, has signed a management agreement with CBRE, the world's largest commercial real estate services firm and provider of critical infrastructure services. CBRE will be the exclusive operations and maintenance provider for building one, Fermi's first data center in the Texas Panhandle. It runs five years from the day building one is first ready for service, and Fermi can renew it in five-year terms. "We're locking in proven partners early to make our operations and construction activities as safe and efficient as possible," said Lee McIntire, Fermi Chief Executive Officer. "CBRE runs some of the most demanding data center environments in the world. Bringing them in now means that when building one is ready for service, the people, the programs, and the procedures to run it are already in plac
LiberNovo Opens Business & Bulk Ordering Ahead of Its Fall Prime Sale24.9.2026 06:50:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / September 24, 2026 / LiberNovo has opened its Business & Bulk Orders section ahead of the Fall Prime Sale, which runs at eu.libernovo.com and uk.libernovo.com. Team ordering goes live on 23 September, and seasonal sale pricing opens 30 September, with a flash sale on selected products on 6-7 October. Discounts reach up to 39% off, and every order is covered by 30-Day Price Protection. Ordering for a team, not a desk Business & Bulk Orders is live from today, covering orders of five chairs or more across the Omni and Maxis series - chairs alone or paired with a footrest - with tiered pricing at five to ten units and again at eleven or more. Discount rates and how they combine with the rest of the sale are set out on each regional page. The timing follows how companies buy: budgets close in the autumn, workstations get specified for the year ahead, and wellbeing programmes are agreed before January. Why October October is National Ergonomics Month. Hybri
OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions23.9.2026 14:25:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Uniso
SmartVendor Brings Autonomous Retail to the Czech Parliament; Clears Europe's Toughest Privacy Bar with SHEKEL WeightAI(TM)23.9.2026 11:20:00 CEST | Press release
PRAGUE, CZ / ACCESS Newswire / September 23, 2026 / SmartVendor today announced the deployment of an autonomous, AI-powered retail solution inside the Chamber of Deputies of the Parliament of the Czech Republic, built on the WeightAI™ platform from SHEKEL Scales Ltd., the weight-based AI technology and solution provider behind the next generation of autonomous retail. For public institutions across Europe, autonomous retail has presented a compliance contradiction: the technology that makes unattended stores work typically relies on cameras, and cameras mean GDPR risk. The Czech Parliament resolved that contradiction by choosing a solution built on WeightAI™. No cameras. No biometrics. No personal data captured at the point of purchase. Full GDPR compliance by design. The installation, deployed by SmartVendor on the Innovendi Elite platform, marks one of the first deployments of an autonomous AI-powered retail solution inside a major state institution in the Czech Republic. Members of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom